Preclinical Study of Qingbai Lotion and Clinical Trial for Treatment of Scalp Psoriasis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048234

Enrollment

Unknown

Registered

2021-07-05

Start date

2022-04-02

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scalp Psoriasis

Interventions

Experimental group:Qingbai lotion

Control group:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years. 2. Meet the diagnostic criteria for psoriasis vulgaris. 3. There are skin lesions on the scalp. 4. Winter type, stable patients. 5. Patients with mild to moderate scalp disease (IGA score 2-3 points or PSSI score 12-18 points). 6. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to the related drug components of Qingbai Lotion. 2. Women who are pregnant, planning to become pregnant or breastfeeding. 3. Topical glucocorticoids, calcipotriol and retinoic acid have been used on the scalp within 2 weeks. 4. Systemic use of glucocorticoids, immunosuppressive agents, retinoic acid drugs, and oral traditional Chinese medicine within 4 weeks. 5. The use of biological agents within the past week.

Design outcomes

Primary

Measure	Time frame
Investigator's global assessment, IGA;Patient's global assessment, PaGA;Psoriasis scalp severity index, PSSI;Scalp life quality index, SLQI;Appearance of dermoscopy;Degree of itching;	—

Countries

China

Contacts

Public ContactCui Bingnan

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

cbn1998@163.com+86 15010459211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026